Blockade of inhibitory receptors such as cytotoxic T-lymphocyte associated protein 4 (CTLA-4) or the Programmed cell death 1 (PD-1)/PD-L1 axis on T lymphocytes is another major strategy applied in cancer immunotherapy [29]. The gene discussed is PDCD1; the disease is cancer.